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Anti-oxidative activityMost coronary deaths occur in patients older than 65 years. Age associated alterations in the composition and
function of high-density lipoproteins (HDL) may contribute to cardiovascular mortality. The effect of advanced
age on the composition and function of HDL is not well understood.
HDL was isolated from healthy young and elderly subjects. HDL composition, cellular cholesterol efﬂux/
uptake, anti-oxidant properties and paraoxonase activity were assessed. We observed a 3-fold increase
of the acute phase protein serum amyloid A, an increased content of complement C3 and proteins involved in
endopeptidase/protease inhibition in HDL of elderly subjects, whereas levels of apolipoprotein E were signiﬁ-
cantly decreased. HDL from elderly subjects contained less cholesterol but increased sphingomyelin. Most
importantly, HDL from elderly subjects showed defective antioxidant properties, lower paraoxonase 1 activity
and was more rapidly taken up by macrophages, whereas cholesterol efﬂux capability was not altered.
These ﬁndings suggest that aging alters HDL composition, resulting in functional impairment that may con-
tribute to the onset/progression of cardiovascular disease.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Cardiovascular disease (CVD) is the leading cause of death world-
wide. CVD rises dramatically with age and is of major concern in the
increasing elderly population. Epidemiological studies have shown
that high-density lipoprotein (HDL) cholesterol levels are inversely
associated with risk for CVD [1]. The protective effect of HDL has
been classically attributed to its ability to promote reverse cholesterol
transport, a series of processes by which HDL is able to transport
cholesterol from the periphery back to the liver for excretion [2]. Of
particular interest, the ability of HDL to promote cholesterol efﬂux
was found to be a better predictor for CVD than HDL-cholesterol [3].
In addition to its role in reverse cholesterol transport, HDL was found
to inhibit low-density lipoprotein oxidation, to inhibit the secretion of
pro-inﬂammatory mediators from macrophages, to reduce adhesion
molecule expression on endothelial cells, to stimulate nitric oxide for-
mation and to promote vasodilatation [4–8].
However, latest failures of HDL-cholesterol raising drugs anda recent
study that showed no causal association between risk formyocardial in-
farction and genetically raised plasma HDL-cholesterol have called into
question whether HDL-cholesterol is a suitable surrogate marker for
HDL-related risk assessment [9,10].: +43 316 380 9645.
. Marsche).
.V. Open access under CC BY license.Recent proteomic studies provided convincing evidence that in-
ﬂammation alters the protein composition of HDL thereby generating
dysfunctional or even pro-atherogenic forms of HDL [11] by enriching
pro-inﬂammatory proteins such as serum amyloid A (SAA), apoC-III
or complement component 3 [12–20]. In addition, inﬂammation
leads to marked alterations in the lipid moiety of HDL, highlighted
by a signiﬁcant reduction in phospholipids [21–23].
These important studies linked compositional alterations of HDL
with functional impairment of HDL, suggesting that even in the absence
of low HDL-cholesterol levels, dysfunctional HDL may be causally in-
volved in the development and progression of cardiovascular disease.
Therefore, it is becoming increasingly apparent that direct measures
of HDL function are needed rather than relying on surrogate markers
such as the concentration of HDL-cholesterol.
Data on the effect of aging on HDL composition and function are lim-
ited. Associations of inﬂammation with age-related pathologies are doc-
umented; however, there is little information available how healthy
aging impacts HDL composition and function. Initial studies reported
that HDL from elderly subjects has a reduced potency to promote choles-
terol efﬂux and to inhibit LDL oxidation [24,25]. In the present study, we
assessed the impact of healthy aging on HDL composition and function.
2. Methods
2.1. Characteristics of study subjects and blood collection
All subjects were considered healthy and clinical characteristics are
given in Table 1. Exclusion criteria included any history of cardiovascular
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subjects showed clinical signs of inﬂammation. Study subjects were free
of lipid-lowering medication and anti-inﬂammatory drugs.
Blood was sampled from healthy subjects after obtaining written in-
formed consent, according to a protocol approved by the Institutional
Review Board of the Medical University of Graz (Nr.: 21-523 ex 09/10).
Blood was collected in serum tubes (Greiner, Kremsmünster, Austria).
2.2. Isolation of HDL
Serum density was adjusted with potassium bromide (Sigma-
Aldrich Corporation, Vienna, Austria) to 1.24 g/mL and a two-step
density gradient was generated in centrifuge tubes (16 × 76 mm,
Beckman Instruments) by layering the density-adjusted plasma
(1.24 g/mL) underneath a NaCl-density solution (1.006 g/mL) as de-
scribed [26,27]. Tubes were sealed and centrifuged at 90.000 rpm for
4 h in a 90 Tiﬁxed angle rotor (Beckman Instruments, Krefeld, Germany).
After centrifugation, the HDL-containing band was collected, desalted via
PD10 columns (GEHealthcare, Vienna, Austria) and immediately used for
experiments or stored at−70 °C.
2.3. Determination of plasma and HDL lipid composition
Levels of total cholesterol, non-esteriﬁed cholesterol, triglycerides,
choline-containing phospholipids (DiaSys Diagnostic Systems GmbH,
Holzheim, Germany) and sphingomyelin (Cayman Europe, Tallinn,
Estonia) were measured enzymatically with commercially available kits.
Sphingomyelin values were subtracted from total choline-containing
phospholipids to quantify phosphatidylcholine. LDL cholesterol was cal-
culated according to the Friedewald equation using HDL cholesterol
values measured in the supernatant of the phosphotungstic acid/MgCl2
precipitation.
2.4. Biochemical quantiﬁcation of HDL-associated proteins
ApoA-I, apoA-II, apoC-II, apoC-III and apoE (Greiner, Flacht, Germany)
were determined by immunoturbidimetry. All lipoprotein analyseswere
performed on an Olympus AU640 analyzer (Olympus Diagnostika,
Hamburg, Germany). Serumamyloid A (SAA) (Life Technologies, Vienna,
Austria) and clusterin (BioVendor R&D, Candler, NC) were determined
using enzyme-linked immunosorbent assays.
2.5. LC–MS/MS analysis
Proteomic proﬁling of HDL was performed as previously described
[28]. HDL was digested with trypsin and the resulting peptides were
separated by nano-HPLC. The sample was ionized in the nanospray
source equipped with nanospray tips and analyzed in a LTQ-FT mass
spectrometer (Thermo Scientiﬁc, Waltham, US). The standard devia-
tion of spectral counts was below 10% between duplicates. Spectral
counts were recorded and used for data analysis by searching theTable 1
Clinical characteristics of study subjects.
Young Elderly
n 26 20
Age (yr) 26.6 (25.4–28.7) 67.2 (65.4–69.2)*
Male/female 13/13 9/11
CRP (mg/dL) 0.1 (0.0–0.2) 0.9 (0.5–2.9)
Total cholesterol (mg/dL) 174 (159–195) 225 (200–239)*
Triglycerides (mg/dL) 68 (54–102) 114 (89–130)
HDL-cholesterol (mg/dL) 55 (47–69) 56 (44–68)
LDL-cholesterol (mg/dL) 97 (85–113) 134 (122–160)*
SAA (mg/dL) 0.8 (0.4–1.5) 2.0 (0.8–7.9)**
Results are given as medians with interquartile range in brackets. Signiﬁcances were
accepted at the level of *P b 0.05.human SwissProt public database downloaded on May 4th 2011
with Spectrum Mill Rev. A.03.03.084 SR4 (Agilent Technologies,
Vienna, Austria). Detailed search criteria were: trypsin; max. missed
cleavage sites: 2; carbamidomethylation at cysteine as ﬁxed modiﬁ-
cation; variable modiﬁcation: oxidized methionine; precursor mass
tolerance+/−0.05 Da; product mass tolerance +/−0.7 Da. Protein
hits were subjected to automatic validation by Spectrum mill: for
precursor charge of 2: score threshold 6.0, percent scored peak in-
tensity (%SPI) threshold 60.0, Fwd-Rev score threshold 2.0 and
rank 1-2 score threshold 2.0; for precursor charge of 1: score thresh-
old 6.0, %SPI threshold 70.0, Fwd-Rev score threshold 2.0 and rank
1-2 score threshold 2.0; for precursor charge of 3: score threshold
8.0, %SPI threshold 70.0, Fwd-Rev score threshold 2.0 and rank 1–2
score threshold 2.0.
2.6. Advanced oxidation protein products (AOPP) assay
AOPPs have been determined as described previously with modiﬁ-
cations [29,30]. Brieﬂy, serumwas depleted of apoB-containing lipopro-
teins with polyethylenglycol (PEG). 400 μL PEG-solution (20% PEG in
200 mmol/L glycine, pH = 7.4)was addedpermL serumand incubated
for 20 min at RT. Precipitate was pelleted (10,000 rpm, 30 min, 4 °C)
and the supernatant used for AOPP detection. Subsequently, 10 μL
apoB-depleted serum was mixed with 40 μL 0.2 mol/L citrate buffer
and incubated for 2 min on a shaker. Afterwards, absorbance was
measured at 340 nm. AOPP were calibrated with chloramine-T (linear
within the range of 0 to 100 μmol/L) and were expressed as μmol/L of
chloramine-T equivalents.
2.7. Arylesterase activity assay
Ca2+-dependent arylesterase activity was determined with a pho-
tometric assay using phenylacetate as the substrate. HDL (0.5 μg pro-
tein) was added to 200 μL buffer containing 100 mmol/L Tris,
2 mmol/L CaCl2 (pH 8.0) and phenylacetate (1 mmol/L). The rate of
hydrolysis of phenylacetate was monitored by the increase of absor-
bance at 270 nm and readings were taken every 30 s at room temper-
ature to generate a kinetic plot. The slope from the kinetic chart was
used to determine ΔAb270nm/min. Enzymatic activity was calculated
with the Beer−Lambert Law from the molar extinction coefﬁcient of
1310 mol1*L−1*cm−1 for phenylacetate.
2.8. Lp-PLA2 activity assay
Lp-PLA2 was measured using commercially available photometric
assay (Cayman Europe, Talinn, Estonia).
2.9. LCAT, PLTP and CETP activity assay
LCAT was measured with a commercially available kit from Merck
(Darmstadt, Germany). PLTP and CETP were measured with assay kits
from Abnova (Eubio, Vienna, Austria).
2.10. Determination of the anti-oxidative capacity of HDL
The anti-oxidative activity of HDLwas determined as previously de-
scribed [31]. Brieﬂy, dihydrorhodamine (DHR)was suspended in DMSO
to a 50 mmol/L stock, which was diluted in HEPES (20 mmol/L HEPES,
150 mmol/L NaCl, pH 7.4) to a 50 μmol/L working reagent. 7.5 μg HDL
protein was placed in a 384-well, 15 μL of DHR working reagent was
added and the volume completed to 100 μL with HEPES buffer. The in-
crease in ﬂuorescence due to the oxidation of DHR was measured
every 2 min for 1 h at 538 nm. The increase in ﬂuorescence per minute
was determined for samples containing only DHR and for samples
containing DHR and individual HDL probes from study subjects.
Table 2
HDL composition.
μg/mg protein Young Elderly
A) Lipids
Total cholesterol 245 ± 40 217 ± 35⁎
Cholesterylester 178 ± 29 164 ± 27
Free cholesterol 63 ± 14 52 ± 10⁎
Triglycerides 47 ± 26 54 ± 26
Phospholipids 450 ± 69 423 ± 58
Sphingomyelin 52 ± 10 61 ± 9⁎
B) Proteins
apoA-I 535 ± 69 560 ± 48
apoA-II 149 ± 23 158 ± 21
apoC-II 5.5 ± 2.2 5.2 ± 2.6
apoC-III 23.5 ± 6.6 23.9 ± 8.0
apoE 17.0 ± 6.3 12.3 ± 4.7⁎
Clusterin 0.17 ± 0.08 0.16 ± 0.09
SAA 1.6 ± 1.2 6.8 ± 5.4⁎⁎
Results are given as mean ± SD. Apo, apoprotein; SAA, serum amyloid A.
⁎ P b 0.05.
⁎⁎ P b 0.01.
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Cholesterol efﬂux assay was performed as described previously
[12]. Brieﬂy, THP-1 macrophages, maintained in DMEM with 10%
fetal bovine serum (FBS), were plated in 48-well plates and differen-
tiated with 100 nmol/L phorbol 12-myristate 13-acetate (PMA). LDL
was aggregated by vortexing at maximum speed for 2 min. Cells
were lipid-loaded with 50 μg/mL aggregated LDL and labeled with
[3H]cholesterol (1 μCi/mL) in medium containing 5% FBS for 24 h.
After labeling, cells were washed and equilibrated in serum-free
media containing 0.2% bovine serum albumin for 2 h. To determine
[3H]cholesterol efﬂux, cells were incubated with 50 μg/mL HDL
protein for 3 h at 37 °C. Supernatants were collected for liquid scin-
tillation counting.
2.12. Uptake of HDL-lipids by THP-1 macrophage
HDL was labeled with 1,19-dioctadecyl-3,3,39,39-tetramethy-
lindocarbocyanine perchlorate (DiI) as described previously [32].
Brieﬂy, HDL was incubated with DiI (300 μg DiI per mg HDL protein)
for 18 h at 37 °C and unreacted dye was removed by gel-ﬁltration.
The human monocyte cell line THP-1 was seeded on 48-well
plates in DMEM containing 10% FBS, 50 μg/mL aggregated LDL and
100 nmol/L PMA and grown overnight. Conﬂuent cells were incubated
with 25 μg/mL DiI-labeled HDL in serum-free DMEM, containing
2.5 mg/mL lipid-free BSA for 3 h at 37 °C. Cells were washed twice
with PBS, detached with 100 μL accutase (PAA; Pasching, Austria) and
transferred into ﬂow cytometry tubes. Cells were ﬁxed with formalde-
hyde and DiI-ﬂuorescence was measured by ﬂow cytometry.
2.13. Statistical analysis
Differences in plasma and HDL parameters between the two age
groups were analyzed with the Student's t-test. Comparisons of mul-
tiple groups were done with One-Way ANOVA and Newman–Keuls
post-hoc test. Correlations between compositional and functional
data were determined with the use of Pearson product–moment esti-
mates. Signiﬁcance was accepted at *P b 0.05 and **P b 0.01. Statisti-
cal analyses were performed with SPSS Statistics Version 19.
3. Results
3.1. Aging is associated with altered composition of HDL
HDL was isolated from two groups of healthy subjects, with a mean
age of 27.5 (median of age = 26.6, n = 26) and 68.0 (median of
age = 67.2, n = 20), respectively. The two groups had no signiﬁcant
differences in serum lipid parameters including HDL-cholesterol levels
(Table 1). Levels of C-reactive protein tended to increase, while SAA
was signiﬁcantly increased in serum of elderly subjects (Table 1).
Compositional analysis indicated that HDL from young subjects
differed signiﬁcantly in their protein and lipid composition (Table 2).
HDL from elderly subjects had a reduced content of free and total cho-
lesterol, whereas sphingomyelin content was increased (Table 2). To
identify HDL-associated proteins, we performed immunoturbidimetry
and enzyme-linked immunosorbent analysis (Table 2) for the major
protein constituents and proteomics analysis for all protein constituents
(Table 3). A signiﬁcantly increased content of SAA anda reduced content
of apoprotein E (apoE) was observed in HDL isolated from elderly sub-
jects, whereas apoC-III and clusterin levels were not altered (Table 2).
In addition, shotgun proteomics analysis revealed an increased content
of complement C3 and proteins involved in endopeptidase/protease in-
hibition in elderly subjects, whereas the HDL-associated enzyme
paraoxonase 1 was decreased (Table 3).
Prompted by the observation that HDL composition is markedly
altered, we examined important serum factors involved in theformation/maturation of HDL. We observed that the activity of phos-
pholipid transfer protein (PLTP) was signiﬁcantly higher in serum of
elderly subjects (Fig. 1A), whereas activities of cholesteryl ester
transfer protein (CETP) and lecithin-cholesteryl acyltransferase
(LCAT) were unaltered (Fig. 1B, C).3.2. Aging impairs HDL anti-oxidant capacity and paraoxonase activity
HDL has been reported to exhibit unique anti-oxidative activity
based in part on observations that oxidative changes occur more
slowly in LDL−HDL mixtures than in LDL alone [33]. We observed
that the anti-oxidative activity of HDL to inhibit the oxidation of the
ﬂuorescent dye dihydrorhodamine from elderly subjects was signiﬁ-
cantly lower compared with HDL from younger subjects (Fig. 2C).
Several proteins present on HDL are reported to metabolize lipid-
peroxidation products of phospholipids, cholesteryl esters and triglycer-
ides. Previous data suggested that HDL-associated paraoxonase 1 and/or
lipoprotein associated phospholipase A2 (Lp-PLA2) contribute to the
antiatherogenic activity of HDL [34–37]. We observed a signiﬁcant re-
duction in paraoxonase 1 activity, whereas Lp-PLA2 activity was
unaltered in HDL from elderly subjects (Fig. 2A, B). Interestingly, the im-
pairment of HDL anti-oxidative properties was accompanied by in-
creased formation of serum advanced oxidation protein products
(AOPPs), an established marker of increased oxidative stress (Fig. 2D).3.3. HDL-lipids from elderly subjects are taken up more rapidly by
macrophages
A major determinant of plaque progression or regression rate is the
balance between cholesterol uptake versus efﬂux pathways. To investi-
gate the impact of age on the activity of HDL to remove cholesterol from
macrophages, we analyzed the capacity of HDL from young and elderly
subjects to mediate cholesterol uptake and cholesterol efﬂux from
lipid-laden THP-1 macrophages. To assess whether HDL-lipid delivery
is altered in elderly subjects, the HDL-lipid moiety was labeled with
the ﬂuorescent lipophilic dye DiI, which is a reliable surrogate to deter-
mine HDL-lipid delivery to cells [38]. We found that HDL from elderly
subjects promoted lipid uptake more efﬁciently than HDL from young
subjects (Fig. 3A). However, HDL from elderly subjects was as efﬁcient
in promoting cholesterol efﬂux from lipid-laden macrophages as HDL
from young subjects (Fig. 3B). Interestingly, cellular DiI-HDL uptake
signiﬁcantly correlated with PLTP activity (Fig. 3C).
Table 3
Identiﬁcation of proteins in HDL isolated from young and elderly healthy subjects.
Access. nr. Protein name Young Elderly
% HDL derived peptides
P02647 Apo A-I 34.91 40.43
P02768 Albumin 13.79 11.39
P02649 Apo E 7.33 5.01
P05090 Apo D 6.18 5.01
P02654 Apo C-I 5.46 4.21
P02652 Apo A-II 4.17 3.99
P35542 SAA4 3.74 3.30
O95445 Apo M 3.30 3.19
P06727 Apo A-4 2.59 3.42
P27169 PON 1 2.59 2.05
P02775 Platelet basic protein 2.01 1.48
P08519 Lp(a) 2.01 1.25
P02656 Apo C-III 1.58 2.28
p02776 Platelet factor 4 1.58 1.59
P02735 SAA1 1.29 2.16
P04114 Apo B-100 1.29 1.14
P02655 Apo C-II 1.15 0.80
P00734 Prothrombin 1.01 1.14
O14791 Apo L1 0.86 0.68
P01009 α-1-Antitrypsin 0.72 1.03
Q13790 Apo F 0.72 0.68
P55056 Apo C-IV 0.43 0.46
Q15166 PON 3 0.43 0.46
PODJI9 SAA 2 0.29 0.57
P01834 IgK chain C region 0.14 0.11
P02766 Transthyretin 0.14 0.34
P02765 α-2-HS-GP 0.14 0.23
P02749 β-2-GP 1 0.14 0.11
POCG05 Igλ chain C region 0.00 0.11
P01857 Igγ chain C region 0.00 0.46
P02763 α-1-Acid GP 1 0.00 0.23
P02787 Serotransferrin 0.00 0.11
P01024 Complement C3 0.00 0.23
Q9BUN1 C1orf56 0.00 0.23
HDL was isolated from young (n = 26) and elderly (n = 20) healthy subjects by
one-step-ultracentrifugation. The HDL proteome was analyzed of pooled fractions by
an LC–MS/MS system and the data were analyzed by searching the human NCBI
nonredundant public database with Mascot 2.2 (MatrixScience). Values shown repre-
sent non-quantitative estimates of the percentage of peptides of the total peptide
count. The peptide count was 787 ± 129. Apo, apoprotein; PON, paraoxonase; SAA,
serum amlyoid A; α-2-HS-GP, α-2-HS-glycoprotein; β-2-GP 1, β-2-HS-glycoprotein.
Fig. 1.Activities of serum enzymes involved in HDLmetabolism. Serum samples from two
groups with a mean age of 27.5 (young, n = 26) and 68.0 (elderly, n = 20) were ana-
lyzed for the activities of (A) phospholipid transfer protein (PLTP), (B) cholesteryl ester
transfer protein (CETP) and (C) lecithin-cholesteryl acyltransferase (LCAT). LCAT activity
is presented as a relative index ranging from 1–2, where 1 indicated complete substrate
conversion and 2 no substrate conversion. Signiﬁcances were accepted at *P b 0.05.
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The data presented here provide evidence that compositional
changes in HDL from elderly subjects are linked to a loss of potential
anti-atherogenic properties of HDL. These ﬁndings raise the possibil-
ity that dysfunctional HDL contributes to the high burden of cardio-
vascular disease in elderly subjects.
The compositional analysis clearly showed that the protein and lipid
cargo of HDL from elderly subjects was profoundly altered, with mark-
edly reduced levels of apoE, whereas several acute-phase proteins,
such as SAA1, SAA2, α-1-antitrypsin, and α-1-acid-glycoprotein1 and
proteins involved in complement activation, such as complement C3,
were enriched. To validate proteomics analyses, we quantiﬁed the
HDL-proteins apoA-I, apoA-II, apoC-II, apoC-III and apoE by
immunoturbidimetry and SAA by enzyme-linked immunosorbent
assays. HDL isolated from elderly subjects showed decreased free
cholesterol content and was enriched in sphingomyelin. ApoE is pro-
duced by cholesterol-loaded macrophages, where it can promote
cholesterol efﬂux during its secretion. ApoE is part of a gene cluster
that is induced in macrophages by cholesterol-sensing nuclear re-
ceptors that protect against atherosclerosis in mice [39]. Interesting-
ly, recent studies reported that chronic inﬂammation markedly
remodels HDL composition associated with increased SAA and com-
plement C3 content in HDL [11–13,16,40]. Complement C3 is pro-
duced by human monocyte-derived macrophages and contributesto innate immunity [41] and has been suggested to contribute to vas-
cular disease [42]. A recent study demonstrated that SAA content in
HDL from patients with chronic kidney disease is being responsible
for pro-inﬂammatory effects of HDL. Incorporation of SAA into control
HDL promoted cytokine production and adhesion molecule expression
on monocytes and myeloid dendritic cells [14]. These ﬁndings are in
line with the recent evidence indicating that SAA stimulates innate im-
mune responses [43]. Of note, recent proteomics analysis of HDL also
revealed that SAA is enriched in patients with acute coronary syn-
drome, psoriasis and rheumatoid arthritis indicating substitution of
anti-inﬂammatory HDL with pro-inﬂammatory HDL during inﬂam-
mation [11–13,16,18,40]. Therefore, increased SAA and complement
C3 content of HDL observed in HDL of elderly subjects suggest that
Fig. 2. Anti-oxidative capacity of HDL is impaired by age. HDL from 26 young subjects and
20 elderly subjectswas analyzed for its anti-oxidative potency. (A) Arylesterase activity of
HDL-associated paraoxonase 1 (PON1) was measured by using phenylacetate as
substrate. (B) Lipoprotein associated phospholipase A2 (Lp-PLA2) activity of HDL was
measured using 2-thio PAF as substrate. The arylesterase and Lp-PLA2 activities of HDL
were calculated from the slopes of the kinetic chart of three independent experiments.
(C) Inhibitory activity of HDL on oxidation was measured by incubating HDL from
young and elderly subjects with dihydrorhodamine (DHR). (D) Advanced oxidation pro-
tein products (AOPPs) were measured in apoB-depleted serum. Signiﬁcances were ac-
cepted at *P b 0.05.
Fig. 3. Increased macrophage uptake of lipids from HDL of elderly subjects. HDL isolat-
ed from 26 young subjects and 20 elderly subjects was examined for its ability to de-
liver lipids or mobilize lipids from macrophages. (A) THP-1 monocytes were
differentiated into macrophages with 100 nM PMA and incubated with DiI-labeled
HDL for 3 h. The uptake of the ﬂuorescent lipophilic dye DiI was quantiﬁed by ﬂow cy-
tometry. Values shown represent means (±SD) of two individual experiments
performed in duplicate. (B) To assess cholesterol efﬂux activity of HDL, [3H]
cholesterol-labeled THP-1 macrophages were incubated with 50 μg/mL HDL for 3 h.
Cholesterol efﬂux is expressed as radioactivity in the supernatant relative to total ra-
dioactivity (in supernatant and cells). Values shown represent means (±SD) of two in-
dividual experiments performed in duplicate. (C) Correlation between phospholipid
transfer protein (PLTP) activity and DiI-HDL uptake of THP-1 macrophages. The Pear-
son correlation coefﬁcients are noted. Signiﬁcances were accepted at *P b 0.05.
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cal roles in the inﬂammatory response and lipid metabolism.
Most importantly, we observed that aging signiﬁcantly alters the
functionality of HDL. HDL-associated paraoxonase 1 was signiﬁcantly
lower in elderly subjects in agreement with previous studies [25,44].
In addition to reduced paraoxonase 1 activity, we observed increased
systemic oxidative stress (measured as serum AOPP levels). This is in
line with recent ﬁndings from genetic and biochemical studies showing
that paraoxonase possesses pronounced systemic anti-oxidant activity
in humans, with coincident links to a reduced risk of cardiovascular
disease [45,46]. A recent clinical study provided evidence that the
anti-oxidative activity of HDL may be of particular importance, since it
was observed that the anti-oxidative capacity of HDL is signiﬁcantly re-
duced in acute coronary syndrome, but not in stable coronary artery dis-
ease [37,47].
In regard to reverse cholesterol transport function of HDL, we ob-
served that HDL-lipids are more rapidly taken up by macrophages
from HDL of elderly subjects. Interestingly, serum PLTP activity
was elevated in elderly subjects and correlated with macrophage
uptake of HDL-lipids. This is in line with previous ﬁndings showing
that elevated serum PLTP activity alters structure and composition
of HDL resulting in increased cellular uptake of HDL-lipids [48,49].
Given that increased PLTP expression was reported in different pa-
thologies associated with high risk of coronary heart disease, such
as obesity, insulin resistance, and type I and II diabetes [50], acceler-
ated uptake of HDL-derived lipids by macrophages might also con-
tribute to cardiovascular risk in these subjects.
Of note, cholesterol efﬂux capacity of HDL did not signiﬁcantly
differ between the examined age groups. This is in line with theobservation that phospholipid content of HDL, a critical component
of the cholesterol acceptor capability of mature HDL, is not altered
in elderly subjects [13,51]. It has to be mentioned that a previous
study reported that cholesterol efﬂux capability of HDL from elderly
subjects is reduced after long-term exposure of 3H-cholesterol la-
beled macrophages (24 h) with HDL [24]. Given that a signiﬁcant
fraction of efﬂuxed 3H-cholesterol is taken up by macrophages within
24 h, an increased re-uptake of HDL-associated3H-cholesterol rather
than a lower cholesterol mobilization capability of HDL may explain
this apparently conﬂicting result.
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The sample size was small, retrospectively analyzed and from a single
institution, and results are associative and do not prove a cause-and-effect
relationship. However, our ﬁndings indicate that the composition of HDL
is altered in elderly subjects andmay help to develop rational therapeutic
strategies that aim to increase HDL functionality. Consequently, the ob-
served age associated alterations of HDL may contribute to the dramati-
cally enhanced risk of cardiovascular disease in elderly subjects.Acknowledgment
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